by Madaline Spencer | Apr 2, 2024
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. ...
by Madaline Spencer | Apr 1, 2024
Among patients with neurologic conditions, Blacks are less likely than Whites to undergo evaluation for genetic testing. Black patients with neurologic conditions are less likely than White patients to undergo evaluation for genetic testing, according to...
by Madaline Spencer | Mar 29, 2024
Alex Kolevzon, MD, Clinical Director of the Seaver Autism Center at Mount Sinai, discusses Phelan-McDermid syndrome and the JAG201 study. Phelan-McDermid syndrome is a rare, genetic form of autism spectrum disorder. It is caused by a variant in the...
by Madaline Spencer | Mar 29, 2024
The U.S. Food and Drug Administration has approved WINREVAIR (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare disorder affecting the heart and lungs. It is characterized by abnormally high blood pressure...
by Madaline Spencer | Mar 27, 2024
The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) that tests positive for anti-aquaporin-4 (AQP4 Ab+). This approval is a major milestone as it...
